The longevity peptide field has expanded rapidly over the past decade. Not every peptide marketed for anti-aging has meaningful evidence behind it. This guide focuses on the peptides with the strongest current evidence base for specific anti-aging applications, ranked by clinical utility and depth of evidence.
The Criteria for "Best"
A peptide earns a place on this list by meeting at least two of the following criteria:
- Published human data (clinical trials or well-documented case series) demonstrating the claimed effect
- Robust and mechanistically consistent preclinical data (animal studies with clear relevance to human biology)
- A well-understood mechanism that directly addresses a validated aging pathway
- An acceptable safety profile at therapeutic doses
Marketing claims and anecdotal reports alone are insufficient.
1. CJC-1295 + Ipamorelin: The Gold Standard GH Protocol
Target: GH/IGF-1 axis decline
The CJC-1295 and ipamorelin combination is the most evidence-backed GH peptide stack available. CJC-1295 provides sustained tonic GH elevation through extended GHRH receptor activation. Ipamorelin amplifies pulsatile GH amplitude with minimal off-target hormonal effects.
Human clinical trials confirm significant and sustained IGF-1 elevation with CJC-1295 use. The downstream effects of restored IGF-1, on muscle mass, fat distribution, bone density, sleep quality, cognitive function, and recovery, touch more domains of biological aging than any other single intervention.
Evidence quality: Clinical trial data (CJC-1295), extensive clinical use data (ipamorelin)
2. Epitalon: Telomere and Circadian Biology
Target: Telomere maintenance, pineal function, circadian rhythm
Epitalon has published evidence for telomerase activation in human somatic cells, improved melatonin secretion in elderly subjects, and positive effects on immune and circadian function in human studies. It is one of the few anti-aging peptides with direct telomere-biology evidence.
Evidence quality: Multiple human studies (primarily from Russian research groups), in vitro human cell data, robust animal longevity data
3. Thymosin Alpha-1: Immune Aging
Target: Immunosenescence, T-cell function, NK cell activity
Thymosin Alpha-1 is the only anti-aging peptide on this list with regulatory approval as a pharmaceutical agent in multiple countries (Zadaxin). Its immune-enhancing effects are supported by multiple randomised controlled trials across various immune conditions. Its longevity relevance is established through the central role of immune aging in biological decline.
Evidence quality: RCT data across multiple indications, pharmaceutical approval in several countries
4. BPC-157: Systemic Tissue Repair
Target: Musculoskeletal repair, gut health, angiogenesis, anti-inflammatory signalling
BPC-157 has an extensive animal model evidence base across multiple tissue types, with consistent positive results for tissue repair, anti-inflammatory effects, and angiogenesis. Human clinical data is emerging.
For anti-aging purposes, BPC-157 addresses the tissue repair deficits that accumulate with age, allowing better maintenance of musculoskeletal integrity throughout the lifespan.
Evidence quality: Extensive animal data, mechanistic clarity, emerging human data
5. GHK-Cu: Tissue Repair and Epigenetic Effects
Target: Collagen synthesis, wound healing, anti-inflammatory signalling, epigenetic longevity effects
GHK-Cu has the most developed clinical evidence base of any skin-relevant anti-aging peptide, with RCT data confirming collagen synthesis, reduced wrinkle depth, and improved skin density. Its broader epigenetic effects, showing gene expression patterns associated with longevity, represent an emerging area of evidence.
Evidence quality: RCT data for skin applications, strong mechanistic data for anti-inflammatory effects, emerging epigenetic data
6. MOTS-c: Mitochondrial Longevity
Target: Mitochondrial function, metabolic regulation, exercise response
MOTS-c is a mitochondrial-derived peptide that acts as an exercise mimetic, activating AMPK-driven metabolic improvements and mitochondrial biogenesis. Published studies in both animals and humans show improved insulin sensitivity, increased energy expenditure, and longevity-associated metabolic changes.
Evidence quality: Human pharmacokinetic data, animal longevity data, emerging human metabolic data
7. Selank and Semax: Neuroprotection and Cognitive Function
Target: Cognitive aging, neuroinflammation, BDNF signalling
Selank and Semax are Russian-developed neuropeptides with regulatory approval in Russia for specific cognitive and anxiety indications. Their BDNF-upregulating and anti-neuroinflammatory effects make them relevant for the cognitive aging component of longevity medicine.
Evidence quality: Human clinical trial data (Russian literature), established pharmaceutical use, mechanistic clarity
Building a Protocol from This List
Not every patient needs every peptide. Protocol design follows from biomarker assessment: which biological aging domains are most advanced determines which peptides are highest priority.
A typical Longegra anti-aging protocol might include:
- Foundation: CJC-1295 + ipamorelin (GH axis)
- Annual cycle: Epitalon (telomere and circadian)
- As indicated: Thymosin Alpha-1 (for patients with immune decline markers)
- For specific goals: GHK-Cu (skin and tissue), MOTS-c (metabolic), BPC-157 (musculoskeletal)
Frequently Asked Questions (FAQs)
When selected and dosed by a physician based on biomarker findings, multi-peptide protocols are safe. The key is ensuring there is no overlap in mechanism that would produce redundant or excessive signalling, and that each peptide has a clear rationale for its inclusion. Longegra's protocols are designed with this principle.
